Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Tuesday Dec 1st, 2009

DrStockPick.com Stock Report!

PWRM, PFE, PLX

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), and Parkinson’s disease (NuroPro-PD) in 2009 and for breast cancer in 2010, followed by filings with the FDA. PWRM operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, and breast cancer.

The NuroPro AD test was developed to help clinicians diagnose patients with Alzheimer’s, as well as to distinguish those with Alzheimer’s from normal individuals and patients with other neurological disorders. The NuroPro test, developed by Power3, utilizes a panel of blood serum protein biomarkers to determine the probability that a patient has Alzheimer’s. The tests are intended to solve a critical challenge facing physicians, clinicians, and patients toward an objective, early stage and accurate diagnosis of actual disease.

“In the US, there are an estimated 5.1 million individuals with Alzheimer’s disease,” said PWRM’s President and Chief Scientific Officer, Dr. Ira L. Goldknopf. “The annual treatment per patient is currently in excess of $30 thousand for Alzheimer’s.”

Recently, PWRM’s advanced blood screening tests for early detection, monitoring and targeting of diseases like Alzheimer’s, Parkinson’s and breast cancer were exposed by Dr. Ira L. Goldknopf to over 50,000 scientists worldwide during the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing.

More about PWRM at www.power3medical.com

**************************************************************

PFE, Pfizer Inc. and PLX, Protalix BioTherapeutics, Inc.

PFE engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.

PLX engages in the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States.

PFE and PLX announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher’s disease. Under the terms of the agreement, PFE will receive exclusive worldwide licensing rights for the commercialization of taliglucerase alfa, while PLX will retain the exclusive commercialization rights in Israel. Taliglucerase alfa is the first enzyme replacement therapy derived from a proprietary plant cell-based expression platform using genetically engineered carrot cells.

With the successful completion of Phase III clinical studies, PLX is preparing to complete a rolling New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The FDA has granted Orphan Drug designation and Fast Track status, facilitating the development and expediting the review of drugs to treat rare conditions or diseases, as well as an Emergency Use Authorization. The FDA has also requested, and subsequently approved, an Expanded Access Program (EAP) treatment protocol. Taliglucerase alfa is currently being provided to Gaucher’s patients in the U.S. under the EAP protocol, as well as to patients in the European Union under a compassionate use protocol.

Under the agreement, PFEwill make an upfront payment of $60 million to PLX. In addition, PLX is eligible to receive additional regulatory milestone payments of up to $55 million. PFE and PLX will share future revenues and expenses for the development and commercialization of taliglucerase alfa on a 60 percent/40 percent basis respectively.

More about PFE at www.pfizer.com

More about PLX at www.protalix.com

**************************************************************

Keep a close eye on PWRM, PFE and PLX, do your homework, and like always BE READY for the ACTION!

***********Advertisement***********

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com End Of day publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.

Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick Stock Watch report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and it has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).

_______________________________________________________

_______________________________________________________

Dr. Stock Pick is a seasoned equity trader and financial investor. He’s on the Crown Equity Holdings, Inc (CRWE.OB) financial staff as a professional investment analyst and consultant. He’s syndicated on over 1400 websites www.crwenews.com, www.stock-ir.com, www.PennyOmega.com, www.BestOTC.com, www.stock-pr.com giving daily, up to the minute information about stocks, options, currencies and more. www.drstockpick.com

email: investor@drstockpick.com

Dr Stock Pick would like to invite you to www.crowntradingsystems.com so you can check out the super 16 multi monitor super computer he trades on daily. If you’re looking for a multi display computer to enhance your trading then you’ll want to visit www.crowntradingsystems.com